ESPR250117C2500
- 0.10
- -0.02-16.67%
Esperion Therapeutics Newsroom
Express News | Esperion Strengthens Balance Sheet With Closing of Significant Refinancing Transactions
Goldman Sachs Upgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Raises Target Price to $4
Cantor Fitzgerald Initiates Esperion Therapeutics(ESPR.US) With Buy Rating, Announces Target Price $8
Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target
12 Health Care Stocks Moving In Friday's Pre-Market Session
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $6
Esperion Therapeutics Price Target Maintained With a $6.00/Share by Needham
Esperion Enters Privately Negotiated Exchange And Subscription Agreements With Certain Holders Of 4.00% Convertible Senior Subordinated Notes Due 2025
Esperion Announces $210M Convertible Debt Financing
Press Release: Esperion Announces $210 Million Convertible Debt Financing
Express News | Esperion Announces $210 Million Convertible Debt Financing
Express News | Esperion Therapeutics Inc: Under Terms of Agreement, Esperion Will Receive an Upfront and Near-Term Milestone Payments
Express News | Esperion Partners With Neopharm to Commercialize Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe) in Israel
Jefferies Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $5
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
Esperion Announces New Drug Submissions in Canada for NEXLETOL (Bempedoic Acid) and NEXLIZET (Bempedoic Acid and Ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
Express News | Esperion Therapeutics Inc - No Serious Adverse Events Observed in Bempedoic Acid Trial
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
Esperion Therapeutics Analyst Ratings